A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
for
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer,
Location: Boston MA, Philadelphia PA, Charlotte NC, Germantown TN,
Sponsor: Hoffmann-La Roche
Sex: Female
Age: 18+
Code: NCT04802759
Phase1, Phase2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
for
Metastatic Breast Cancer
Location: Moncton, Boston MA, Quebec, Montreal, Hyattsville MD,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT05894239
Phase3, Recruiting
Featured
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Sterling Heights MI, Fountain Valley CA
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase3, Recruiting
Featured
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
for
Breast Cancer
Location: East Brunswick NJ, Jacksonville FL, Los Angeles CA
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07368998
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: East Patchogue NY, The Bronx NY, New Brunswick NJ,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase1, Phase2, Recruiting
Featured
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Moncton, The Bronx NY, New York NY, East Brunswick NJ,